1. Introduction 1.1 Market Definition 2. Research Methodology 3. Executive Summary 4. Key Inferences 5. Market Overview 5.1 Current Market Scenario 5.2 Porter's Five Forces Analysis 5.2.1 Bargaining Power of Suppliers 5.2.2 Bargaining Power of Consumers 5.2.3 Threat of New Entrants 5.2.4 Threat of Substitute Product and Services 5.2.5 Competitive Rivalry within the Industry 6. Drivers, Restraints, Opportunities and Challenges Analysis (DROC) 6.1 Market Drivers 6.1.1 Ease in Regulatory Approval for Novel Cancer Therapy in Europe 6.1.2 Increase in Heathcare Speding for Cancer 6.1.3 Rising Prevalence of Cancer in Europe 6.1.4 Strong R&D Initiatives from Key Players 6.2 Market Restraints 6.2.1 Inequality in Access of Cancer Therapy across Europe 6.2.2 High Cost of Cancer Therapies 6.3 Opportunities 6.4 Key Challenges 7. Market Segmentation 7.1 By Therapy Type 7.1.1 Chemotherapy 7.1.2 Targeted Therapy 7.1.3 Immunotherapy (Biologic Therapy) 7.1.4 Hormonal Therapy 7.1.5 Others 7.2 By Cancer Type 7.2.1 Blood Cancer 7.2.2 Breast Cancer 7.2.3 Prostate Cancer 7.2.4 Skin Cancer 7.2.5 Respiratory/Lung Cancer 7.2.6 Others 7.3 By End User 7.3.1 Hospitals 7.3.2 Specilty Clinics 7.3.3 Cancer and Radiation Therapy Centers 7.4 By Geography 7.4.1 Europe 7.4.1.1 France 7.4.1.2 Germany 7.4.1.3 United Kingdom 7.4.1.4 Italy 7.4.1.5 Spain 7.4.1.6 Rest Of Europe 8. Competitive Landscape 8.1 Mergers & Acquisition Analysis 8.2 Agreements, Collaborations, and Partnerships 8.3 New Products Launches 9. Key Players 9.1 Amgen 9.2 AstraZeneca 9.3 Bayer AG 9.4 Bristol-Meyrs Squibb Company 9.5 F. Hoffmann-La Roche Ltd 9.6 GlaxoSmithKline PLC 9.7 Johnson & Johnson 9.8 Merck & Co. Inc. 9.9 Novartis AG 9.10 Pfizer Inc. 9.11 Others 10. Future of the Market

AMGEN. ASTRAZENECA, BRISTOL-MEYRS SQUIBB COMPANY, BAYER AG, F. HOFFMANN-LA ROCHE LTD., GLAXOSMITHKLINE PLC, JOHNSON & JOHNSON, MERCK & CO., INC., NOVARTIS AG, AND PFIZER INC.